PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33791811-9	2021	Also, sorafenib significantly decreased the levels of P21, CyclinD1, CDK4 and proliferating cell nuclear antigen, as well as up-regulated P53 expression in adjuvant arthritis fibroblast-like synoviocytes.	Sorafenib	6-15	KRAS proto-oncogene, GTPase	Rattus norvegicus	54-57	
29275358-13	2018	Sorafenib-resistant HCC cells showed elevated KRAS expression, and KRAS inhibition resensitised sorafenib-resistant cells to suppression of proliferation and induction of apoptosis.	Sorafenib	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	46-50	
29275358-13	2018	Sorafenib-resistant HCC cells showed elevated KRAS expression, and KRAS inhibition resensitised sorafenib-resistant cells to suppression of proliferation and induction of apoptosis.	Sorafenib	96-105	KRAS proto-oncogene, GTPase	Rattus norvegicus	67-71	
29275358-14	2018	CONCLUSIONS: KRAS is dysregulated in HCC by loss of tumour-suppressive microRNA-622, contributing to tumour progression, sorafenib sensitivity and resistance.	Sorafenib	121-130	KRAS proto-oncogene, GTPase	Rattus norvegicus	13-17	
27916938-3	2016	In this study, we explored sorafenib-induced cellular effects in Kirsten rat sarcoma viral oncogene homolog olog (KRAS) wild-type and KRAS-mutated CRC cell lines (Caco-2 and HRT-18), and finally profiled expression changes of specific miRNAs within the miRNome (>1000 human miRNAs) after exposure to sorafenib.	Sorafenib	27-36	KRAS proto-oncogene, GTPase	Rattus norvegicus	114-118	
27916938-3	2016	In this study, we explored sorafenib-induced cellular effects in Kirsten rat sarcoma viral oncogene homolog olog (KRAS) wild-type and KRAS-mutated CRC cell lines (Caco-2 and HRT-18), and finally profiled expression changes of specific miRNAs within the miRNome (>1000 human miRNAs) after exposure to sorafenib.	Sorafenib	27-36	KRAS proto-oncogene, GTPase	Rattus norvegicus	134-138